Hepatitis B Virus Reactivation in Patients Receiving Bruton Tyrosine Kinase Inhibitors.

Chia-Yu Chiu,Sairah Ahmed,Sheeba K Thomas,Lan Sun Wang,Khalis Mustafayev,Luis E Fayad,William G Wierda,Fareed Khawaja,Harrys A Torres

Clinical lymphoma, myeloma & leukemia（2023）

引用 0|浏览14

暂无评分

摘要

HBV reactivation risk is intermediate in patients with past HBV infection who receive BTK inhibitors. For patients with past HBV infection who received BTK inhibitors, data are insufficient to recommend universal anti-HBV prophylaxis, but monitoring for HBV reactivation is warranted.

查看译文

关键词

Acalabrutinib, Ibrutinib, Hepatitis B, Hepatitis flare, Zanubrutinib

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要